An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa
Division
North Florida
Hospital
Capital Regional Medical Center
Document Type
Review Article
Publication Date
3-1-2024
Keywords
hidradenitis suppurativa, treatment, secukinumab, bimekizumab, izokibep, upadacitinib, povorcitinib, eltrekibart
Disciplines
Bacterial Infections and Mycoses | Dermatology | Medicine and Health Sciences | Skin and Connective Tissue Diseases
Abstract
Hidradenitis suppurativa (HS) is a severe, debilitating, chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses and draining sinus tracts in intertriginous areas. While this condition appears to stem from follicular unit dysfunction, its cause is multifactorial and the exact pathogenesis has yet to be fully elucidated. These factors make treatment selection challenging and contribute to variable therapeutic response among affected patients. Typical regimens consist of a combination of medical and surgical modalities, tailored to individual responses. However, HS is often refractory to traditional treatments, prompting the need for newer and more effective therapies. Herein, we review current and emerging HS therapies.
Publisher or Conference
Skin Therapy Letter
Recommended Citation
Miller A, Shahzeidi P, Bernhardt M. An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa. Skin Therapy Lett. 2024;29(2):1-6.